anti-ROR1 CAR NK-cell therapy (TNK Therapeutics/NantKwest)

N/A

Report date: 2025/03/18 18:09:59

Base Information

Drug Nameanti-ROR1 CAR NK-cell therapy (TNK Therapeutics/NantKwest)
Drug Alias NameROR1 targeting CAR-TNK-based immunotherapy (TNK Therapeutics/NantKwest)
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion proteinCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapy > Chimeric antigen receptor NK cell therapy
Mechanisms of ActionInactive tyrosine-protein kinase transmembrane receptor ROR1 modulators
TargetsInactive tyrosine-protein kinase transmembrane receptor ROR1
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesTnk Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesImmunitybio IncTnk Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A